Valuation: Avicanna Inc.

Market Cap 1.68Cr 1.2Cr 1.04Cr 96.89L 88.95L 114.3Cr 1.71Cr 11Cr 4.48Cr 57Cr 4.5Cr 4.4Cr 190.81Cr P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 1.65Cr 1.18Cr 1.02Cr 95.27L 87.47L 112.39Cr 1.68Cr 11Cr 4.41Cr 56Cr 4.42Cr 4.32Cr 187.63Cr EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day+7.33%
1 week-6.93%
1 month+4.27%
3 months-15.73%
6 months-38.16%
Current year-42.81%
1 week 0.09
Extreme 0.0852
0.1
1 month 0.07
Extreme 0.0684
0.1
Current year 0.07
Extreme 0.0684
0.18
1 year 0.07
Extreme 0.0684
0.24
3 years 0.07
Extreme 0.0684
0.53
5 years 0.07
Extreme 0.0684
1.08
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%-6.93% - - 1.2Cr
-0.36%+0.14%-0.95%+14.33% 4.85TCr
-1.83%-2.45%+393.44%+475.29% 3.99TCr
-0.99%+8.86%+27.01%+7.31% 3.87TCr
-1.72%-4.66%+2.11%+50.96% 3.51TCr
-2.41%+2.59%+11.68%+41.16% 2.98TCr
-0.36%-2.65%+32.67%+122.34% 1.61TCr
+0.14%-4.11% - - 1.61TCr
-0.62%+1.23%+1.80%+15.05% 1.36TCr
-3.10%-7.17%-4.93%-37.59% 1.26TCr
Average -0.48%+0.86%+57.85%+86.11% 2.78TCr
Weighted average by Cap. -1.26%+1.82%+75.08%+105.17%

Financials

2024 2025
Net sales 2.55Cr 1.81Cr 1.58Cr 1.47Cr 1.35Cr 173.24Cr 2.59Cr 17Cr 6.79Cr 86Cr 6.82Cr 6.67Cr 289.2Cr 2.55Cr 1.82Cr 1.58Cr 1.47Cr 1.35Cr 173.37Cr 2.59Cr 17Cr 6.8Cr 86Cr 6.82Cr 6.67Cr 289.42Cr
Net income -36.18L -25.79L -22.42L -20.87L -19.16L -25Cr -36.74L -2.46Cr -96.53L -12Cr -96.85L -94.72L -41Cr -27.59L -19.67L -17.1L -15.91L -14.61L -19Cr -28.02L -1.88Cr -73.62L -9.35Cr -73.87L -72.24L -31Cr
Net Debt -3L -2L -2L -2L -2L -2.31Cr -3L -23.03L -9L -1.15Cr -9L -9L -3.85Cr -3L -2L -2L -2L -1L -1.91Cr -3L -19.08L -7L -95.07L -8L -7L -3.19Cr
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
31/26/31 $0.0927 +7.33% 1,000
30/26/30 $0.0864 -10.59% 35,711
29/26/29 $0.0966 +4.32% 6,725
28/26/28 $0.0926 -3.64% 1,100
27/26/27 $0.0961 -3.51% 1,06,000